

Effectiveness and safety of topical 1% terbinafine versus topical 2% sertaconazole in patients with tinea cruris: A randomized controlled trial

Sundiep Kumar¹, Jaishree Noor², Vijay Prakash Gupta^{3*}

¹Assistant Professor, Department Of Dermatology, Rajshree Medical Research Institute, Bareilly, Uttar Pradesh, India

²Assistant Professor, Department of Dermatology, AL-Falah School of Medical Sciences & Research Centre, Dhouj, Haryana, India

³Associate Professor, Department of Dermatology, Rajshree Medical Research Institute, Bareilly, Uttar Pradesh, India

Received: 21-11-2021 / Revised: 06-12-2021 / Accepted: 01-01-2022

Abstract

Introduction: we compare the efficacy of topical terbinafine hydrochloride 1%, a fungicidal agent and sertaconazole nitrate 2% cream, a fungistatic agent in localized tinea corporis and tinea cruris and to study the adverse effects of these antifungal creams. **Materials and Methods:** 80 treatment naive individuals with tinea cruris were randomized into two groups of 30 each of 1:1 ratio using computer random sequence generator (www.randomization.com) to receive either topical terbinafine applied twice daily or topical sertaconazole once daily for a period of 4 weeks. The study pro forma included demographic details of patient, concomitant drugs taken, medical history, and physical and clinical examination which record vitals of patients. **Results:** At the baseline, composite score of all clinical symptoms was 5.11 ± 1.06 in the terbinafine group and 5.61 ± 1.15 in the sertaconazole group which was matched ($P = 0.85$). At the end of treatment (4 weeks), total composite score was 0.09 ± 0.21 in the terbinafine group and 0.04 ± 0.19 in the sertaconazole group which showed statistical significance ($P < 0.001$). Table 2 shows intragroup comparison of mean scores of two groups. **Conclusion:** Terbinafine was equal in efficacy and safety to newer azole – sertaconazole in treating patients with tinea cruris.

Keywords: Tinea cruris, sertaconazole, Terbinafine, efficacy

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>) and the Budapest Open Access Initiative (<http://www.budapestopenaccessinitiative.org/read>), which permit unrestricted use, distribution, and reproduction in any medium, provided original work is properly credited.

Introduction

One of the common varieties of tinea encountered is tinea cruris (12–27%). It is often seen at inguinal folds bilaterally and presents with erythematous plaque and pruritus. Dermatophytic infections can be treated by systemic as well as topical treatment. However, topical antifungals alone are usually sufficient for localized dermatophyte infections, avoid the systemic side effects, and can be easily applied[1]. Numerous studies have shown that allylamine like terbinafine is better to azoles in treating tinea infections and considered to have broad spectrum of antifungal activity[2]. However, sertaconazole one of the newer azoles with both fungicidal and fungistatic action, which is structurally unique with benzothioephene ring, which prolongs duration of action in stratum corneum approximately 48 h and this results in reduction in relapse rate and better mycological cure[3]. Furthermore, sertaconazole has additional anti-inflammatory, anti-pruritic actions and applied topically once a day[4,5].

Many topical antifungals of different groups are available for the treatment of dermatophytoses such as azole derivatives, allylamines, benzylamines, morpholine, etc., Systemic drugs, such as terbinafine and itraconazole, are currently used for the treatment of severe and chronic dermatophytosis[6]. Topical antifungal drugs are effective in localized infections. Topical antifungal therapy based on the use of imidazoles, such as clotrimazole, miconazole, and ketoconazole, is most commonly used[7].

Sertaconazole is a newer topical antifungal agent which belongs to the imidazole class of antifungals. Like other azoles, sertaconazole inhibits the synthesis of ergosterol, an essential component of fungal cell walls resulting in disruption of mycelial growth and replication. However, at higher concentrations, sertaconazole binds directly to non-sterol lipids in the fungal cell wall, which leads to increased permeability and subsequent lysis of the mycelium. Thus, depending on concentration, sertaconazole may exhibit both fungistatic and fungicidal activities[8].

Terbinafine hydrochloride is one of the fungicidal allylamine groups of drugs with broad spectrum of antifungal activity. It interferes with fungal sterol biosynthesis at an early stage. It also inhibits squalene epoxidation, leading to intracellular accumulation of toxic squalene responsible for fungal cell death[9]. There is paucity of clinical studies regarding the clinical efficacy of newer antifungal like sertaconazole in treatment of tinea corporis and tinea cruris.

As per our knowledge, there is not a single study available at present comparing the clinical efficacy of topical terbinafine and sertaconazole cream in treatment of tinea corporis and tinea cruris. With this background the present trial was carried out to study and compare the efficacy of topical terbinafine hydrochloride 1%, a fungicidal agent and sertaconazole nitrate 2% cream, a fungistatic agent in localized tinea corporis and tinea cruris and to study the adverse effects of these antifungal creams.

Materials and methods

Patients aged 18–65 years with either gender who had localized tinea lesions limited to inguinal region, agreed to give written informed consent were included after taking clearance from the Institutional Ethics Committee. Patients with secondary bacterial infections, diabetic, immunocompromised patients, and on other antifungals were

*Correspondence

Dr. Vijay Prakash Gupta

Associate Professor, Department of Dermatology, Rajshree Medical Research Institute, Bareilly, Uttar Pradesh, India

E-mail: drvijayderma26@gmail.com

excluded from the study. We excluded patients having drug history of hypersensitivity to azole as well as allylamine group and women with pregnancy and lactation.

80 treatment naive individuals with tinea cruris were randomized into two groups of 30 each of 1:1 ratio using computer random sequence generator (www.randomization.com) to receive either topical terbinafine applied twice daily or topical sertaconazole once daily for a period of 4 weeks. The study pro forma included demographic details of patient, concomitant drugs taken, medical history, and physical and clinical examination which record vitals of patients, also regarding the prescription of drug given by the treating doctor was collected. Relevant investigations (potassium hydroxide [KOH] mount) were done at the first (baseline) visit and followed up at 2 and 4 weeks.

It was possible to get sufficient scales at baseline and at the end of 1

week of treatment for mycological assessment but due to good treatment response there were hardly any scales to perform the mycological assessment at the end of 2nd and 3rd weeks. We performed the mycological assessment with whatever scales available at the end of 2nd and 3rd week.

Mycological cure was defined as negative KOH and culture. Complete cure was defined as mycological cure with complete absence of clinical signs and symptoms.

Statistical analysis was done using Student's paired and unpaired *t*-tests from the data obtained.

Results

80 patients with tinea cruris fulfilling the inclusion criteria were analyzed in our study. The baseline parameters were matched between two groups and presented in Table 1.

Table 1: Baseline parameters

Parameters	Terbinafine cream	Sertaconazole cream	P value
Age in years			0.86*
Mean (standard deviation)	35.01 (12.61)	34.63 (11.06)	
Gender – n (%)			0.68**
Male	31 (86.61%)	32 (91%)	
Female	9 (13.31%)	8 (13%)	
Baseline mean score	5.11 ± 1.06	5.61 ± 1.15	0.09*

*Data analyzed using unpaired *t* test, **data analyzed using Fisher's exact test, *P* < 0.05 – statistically significant

At the baseline, composite score of all clinical symptoms was 5.11 ± 1.06 in the terbinafine group and 5.61 ± 1.15 in the sertaconazole group which was matched (*P* = 0.85). At the end of treatment (4 weeks), total composite score was 0.09 ± 0.21 in the terbinafine group and 0.04 ± 0.19 in the sertaconazole group which showed statistical significance (*P* < 0.001). Table 2 shows intragroup comparison of mean scores of two groups.

Table 2: Mean scores of primary efficacy parameters: Comparison of intragroup

Parameters	Baseline	2 nd week	4 th week	P value
Terbinafine				
Pruritus	3.01±0.51	0.89±0.45	0.09±0.29	<0.001*
Erythema	1.62±0.52	1±0.66	0±0.00	<0.001*
Desquamation	0.51±0.52	0.09±0.26	0±0.00	<0.001*
Sertaconazole				
Pruritus	3.43±0.58	1±0.43	0±0.00	<0.001*
Erythema	1.55±0.59	0.88±0.59	0.05±0.19	<0.001*
Desquamation	0.72 ± 0.54	0.18 ± 0.39	0 ± 0.00	<0.001*

Discussion

Most common symptoms of fungal infection are vesicles, redness, pruritus, and desquamation. Higher recurrence rate is because of patients receiving inadequate therapy [1]. The main aim of the antifungal therapy is to reduce the morbidity associated with tinea infections. In our study, the efficacy and safety of terbinafine and sertaconazole applied topically in patients with mild-to-moderate tinea cruris was compared. There was improvement in clinical features by reduction of pruritus, redness, vesicles, and desquamation and 100% mycological cure in both the study groups from baseline to 4 weeks. Both the drugs were well tolerated.

The mean age of our enrolled patients was 34.03 ± 11.60 years in the terbinafine group and 34.63 ± 11.06 years in the sertaconazole group which was matched at baseline (*P* = 0.83). Similar age representation was found in the study done by Jerjani *et al* [10], with mean age of 36.45 ± 14.70 in the terbinafine group and 32.33 ± 11.85 in azole group, as most commonly adults were encountered with tinea cruris. Males found to be higher affected with 86% in the terbinafine group and 89% in the sertaconazole group (*P* = 0.68). Similar results in studies of Kumar *et al* [1], and Borgohain *et al* [11], where majority of the patients were male compared to females. This difference in gender distribution may be because of stigma associated with attending hospital.

In a study done by Sharma *et al* [12], on the efficacy and tolerability of sertaconazole nitrate 2% cream vs miconazole 1% cream in patients with cutaneous dermatophytosis, sertaconazole nitrate 2% cream was used twice daily for 2 weeks and they observed that 62.3%

patients had a complete clinical cure. Sertaconazole was well tolerated without clinically significant side effects. In our study, complete cure rates of 73.33% at the end of 2nd week was seen. But we continued the treatment for another 1 week and observed complete cure rate (100%) at the end of the 3rd week.

Esso *et al* [13], in their study of sertaconazole in the treatment of paediatric patients with cutaneous dermatophyte infections used 2% sertaconazole once daily for a period of 2 weeks and observed that clinical cure was achieved in 75% and 100% patients after 2 and 4 weeks, respectively. No local adverse effects were observed in their study. In our study, complete cure rates of 73.33% at the end of 2nd week was seen with application of sertaconazole cream twice daily for 2 weeks. Esso *et al* [13], achieved 75% cure rate with only once daily application of sertaconazole at the end of 2 weeks as compared to twice daily application in our study which could be explained on the basis that in paediatric age group percutaneous absorption is more due to thinner skin as compared to adults.

To the best of our knowledge, till date no study comparing the efficacy and safety of terbinafine hydrochloride 1% cream and sertaconazole nitrate 2% cream has been done.

Our study showed that the newer fungistatic drug sertaconazole nitrate 2% cream is as effective as terbinafine hydrochloride 1% cream which is one of the fungicidal drugs, though terbinafine hydrochloride 1% cream has higher rates of complete cure at the end of 2 weeks as compared to sertaconazole nitrate 2% cream. Both the drugs showed good tolerability with no adverse effects.

Conclusion

Terbinafine was equal in efficacy and safety to newer azole – sertaconazole in treating patients with tinea cruris. However, sertaconazole has showed a better response to therapy as compared to terbinafine. Mycological cure was achieved in all patients at the completion of therapy indicating no recurrence. Both the study drugs were well tolerated and no serious adverse reactions.

References

1. Kumar VK. A study of comparative assessment of efficacy and safety of sertaconazole 2% cream versus terbinafine 1% cream in patients with dermatophytoses of skin. *J Evid Based Med Healthc* 2015;2:5839-58.
2. Sumyuktha J, Narasimhan M, Ahamed PB. A comparative trial between the therapeutic efficacy of topical 2% Sertaconazole cream and 1% terbinafine cream in the treatment of tinea cruris/tinea corporis. *Int J Res Dermatol* 2017;3:59-63.
3. Carrillo-Muñoz AJ, Tur-Tur C, Cárdenas DC, Estivill D, Giusiano G. Sertaconazole nitrate shows fungicidal and fungistatic activities against *Trichophyton rubrum*, *Trichophyton mentagrophytes* and *Epidermophyton floccosum*, causative agents of tinea pedis. *Antimicrob Agents Chemother* 2011;55:4420-1.
4. Choudhary S, Bisati S, Singh A, Koley S. Efficacy and safety of terbinafine hydrochloride 1% cream vs. sertaconazole nitrate 2% cream in tinea corporis and tinea cruris: A comparative therapeutic trial. *Indian J Dermatol* 2013;58:457-60.
5. Hay RJ, Ashbee HR. Mycology. In: Burns T, Breathnach S, Cox N, Griffiths C, editors. *Rook's Textbook of Dermatology*. 9th ed. Edinburgh: Wiley Blackwell; 2016. p. 1-93.
6. Niewerth M, Korting HC. The use of systemic antimycotics in dermatotherapy. *Eur J Dermatol*. 2000;10:155–60.
7. Suschka S, Fladung B, Merk HF. Clinical comparison of the efficacy and tolerability of once daily canesten with twice daily nizoral (clotrimazole 1% cream vs. ketoconazole 2% cream) during a 28-day topical treatment of interdigital tinea pedis. *Mycoses*. 2002;45:91–6.
8. Croxtall JD, Plosker GL. Sertaconazole: A review of its use in the management of superficial mycoses in dermatology and gynaecology. *Drugs*. 2009;69:339–59.
9. Ryder NS. Terbinafine: Mode of action and properties of the squalene epoxidase inhibition. *Br J Dermatol*. 1992;126:2–7.
10. Jerajani HR, Janaki C, Kumar S, Phiske M. Comparative assessment of the efficacy and safety of sertaconazole (2%) cream versus terbinafine cream (1%) versus luliconazole (1%) cream in patients with dermatophytoses: A pilot study. *Indian J Dermatol* 2013;58:34-8.
11. Borgohain M, Elango P, Chellathai D. Efficacy and safety of topical sertaconazole versus topical terbinafine in the treatment of dermatophytoses in a tertiary care centre. *Int J Basic Clin Pharmacol* 2016;5:855-61.
12. Sharma A, Saple DG, Surjushe A, Rao GR, Kura M, Ghosh S, et al. Efficacy and tolerability of sertaconazole nitrate 2% cream vs. miconazole in patients with cutaneous dermatophytosis. *Mycoses*. 2011;54:217–22.
13. Ezzo DV, Fajo G, Losada I, Vilallonga M, Casanovas JM, Clanxet J, et al. Sertaconazole in the treatment of pediatric patients with cutaneous dermatophyte infections. *Clin Therap*. 1995;17:264–9.

Conflict of Interest: Nil Source of support: Nil